| Literature DB >> 26152112 |
Hayato Yamana1,2, Hiroki Matsui3, Kiyohide Fushimi4, Hideo Yasunaga5.
Abstract
BACKGROUND: Risk adjustment is important in studies using administrative databases. Although utilization of diagnostic and therapeutic procedures can represent patient severity, the usability of procedure records in risk adjustment is not well-documented. Therefore, we aimed to develop and validate a severity index calculable from procedure records.Entities:
Mesh:
Year: 2015 PMID: 26152112 PMCID: PMC4495704 DOI: 10.1186/s12913-015-0889-x
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Characteristics of patients included in the study
| Derivation cohort | Validation cohort | All patients | ||||
|---|---|---|---|---|---|---|
| Total number | 270 054 | 269 331 | 539 385 | |||
| Admission-precipitating diagnosis, n (%) | ||||||
| Acute myocardial infarction | 10 421 (3.9) | 10 176 (3.8) | 20 597 (3.8) | |||
| Congestive heart failure | 56 970 (21.1) | 56 927 (21.1) | 113 897 (21.1) | |||
| Acute cerebrovascular disease | 89 983 (33.3) | 90 071 (33.4) | 180 054 (33.4) | |||
| Gastrointestinal hemorrhage | 35 073 (13.0) | 34 429 (12.8) | 69 502 (12.9) | |||
| Pneumonia | 68 387 (25.3) | 68 386 (25.4) | 136 773 (25.4) | |||
| Septicemia | 9220 (3.4) | 9342 (3.5) | 18 562 (3.4) | |||
| Male, n (%) | 155 273 (57.5) | 154 857 (57.5) | 310 130 (57.5) | |||
| Age, mean (SD) | 74.1 (14.2) | 74.1 (14.2) | 74.1 (14.2) | |||
| Age by category, n (%) | ||||||
| <60 | 37 363 (13.8) | 37 425 (13.9) | 74 788 (13.9) | |||
| 60–69 | 47 235 (17.5) | 46 833 (17.4) | 94 068 (17.4) | |||
| 70–79 | 73 468 (27.2) | 73 509 (27.3) | 146 977 (27.2) | |||
| 80–89 | 84 965 (31.5) | 84 964 (31.5) | 169 929 (31.5) | |||
| ≥90 | 27 023 (10.0) | 26 600 (9.9) | 53 623 (9.9) | |||
| Charlson comorbidity index, n (%) | ||||||
| 0 | 162 038 (60.0) | 161 597 (60.0) | 323 635 (60.0) | |||
| 1 | 34 307 (12.7) | 34 015 (12.6) | 68 322 (12.7) | |||
| 2 | 52 841 (19.6) | 52 688 (19.6) | 105 529 (19.6) | |||
| ≥3 | 20 868 (7.7) | 21 031 (7.8) | 41 899 (7.8) | |||
| In-hospital death, n (%) | 25 638 (9.5) | 25 449 (9.4) | 51 087 (9.5) | |||
| Length of stay in days, median (IQR) | 15 (9–29) | 15 (9–29) | 15 (9–29) | |||
IQR – interquartile range
SD – standard deviation
Procedures with ≥1 % prevalence in the derivation cohort
| Surviving patients (n = 244 416) | Deceased patients (n = 25 638) |
| ||||
|---|---|---|---|---|---|---|
| % | (n) | % | (n) | |||
| Blood chemistry tests | 87.2 | (213 046) | 89.5 | (22 949) | <0.001 | |
| Hematology tests | 86.1 | (210 402) | 88.6 | (22 704) | <0.001 | |
| Plasma protein immunology testsb | 81.0 | (198 064) | 85.4 | (21 896) | <0.001 | |
| Radiography | 78.1 | (190 981) | 81.6 | (20 922) | <0.001 | |
| Electrocardiogram | 69.3 | (169 490) | 69.7 | (17 869) | 0.244 | # |
| Peripheral intravenous infusion | 65.1 | (159 043) | 72.5 | (18 581) | <0.001 | |
| Coagulation tests | 59.5 | (145 418) | 62.2 | (15 937) | <0.001 | |
| Computed tomography scan | 50.6 | (123 559) | 62.2 | (15 938) | <0.001 | |
| Infectious disease immunology testsc | 50.5 | (123 481) | 49.2 | (12 622) | <0.001 | † |
| Hepatitis virus tests | 39.5 | (96 552) | 37.8 | (9681) | <0.001 | † |
| Heart rate/respiration monitoring | 37.4 | (91 457) | 49.8 | (12 770) | <0.001 | |
| Pulse oximetry | 34.9 | (85 254) | 51.2 | (13 128) | <0.001 | |
| Oxygen administration | 30.5 | (74 526) | 54.5 | (13 961) | <0.001 | |
| Urine tests (general) | 32.0 | (78 225) | 35.3 | (9046) | <0.001 | |
| Endocrinology tests | 28.3 | (69 282) | 32.1 | (8222) | <0.001 | |
| Bacterial culture | 25.0 | (61 069) | 34.5 | (8852) | <0.001 | |
| Urine microscopy | 21.6 | (52 891) | 24.2 | (6211) | <0.001 | |
| Immunohematology testsd | 21.8 | (53 197) | 21.4 | (5486) | 0.175 | # |
| Bacterial microscopy | 20.1 | (49 180) | 27.8 | (7127) | <0.001 | |
| Urinary catheter insertion | 18.0 | (43 933) | 37.2 | (9534) | <0.001 | |
| Ultrasound imaging | 18.9 | (46 118) | 18.8 | (4830) | 0.909 | # |
| Magnetic resonance imaging | 18.6 | (45 489) | 10.2 | (2615) | <0.001 | † |
| Acid-fast bacilli culture | 8.5 | (20 879) | 10.6 | (2727) | <0.001 | |
| Bacterial drug susceptibility tests | 7.2 | (17 667) | 12.7 | (3267) | <0.001 | |
| Sputum suction | 5.3 | (13 061) | 22.2 | (5680) | <0.001 | |
| Use of catecholamines or vasopressin | 5.1 | (12 371) | 12.3 | (3143) | <0.001 | |
| Red blood cell transfusion | 5.0 | (12 268) | 5.2 | (1324) | 0.313 | # |
| Nucleic acid amplification tests | 3.7 | (9102) | 4.6 | (1178) | <0.001 | |
| Tumor markers | 3.3 | (8018) | 2.6 | (667) | <0.001 | † |
| Invasive arterial pressure measurement | 2.3 | (5649) | 4.4 | (1130) | <0.001 | |
| Autoantibody tests | 2.3 | (5740) | 1.9 | (488) | <0.001 | † |
| Urine chemistry tests | 2.1 | (5130) | 2.6 | (654) | <0.001 | |
| Gastric drainage tube insertion | 1.6 | (3993) | 6.1 | (1559) | <0.001 | |
| Central venous catheter insertion | 1.2 | (2997) | 5.3 | (1346) | <0.001 | |
| Intratracheal intubation | 0.9 | (2252) | 7.7 | (1963) | <0.001 | |
| Stool tests | 1.4 | (3377) | 1.2 | (311) | 0.027 | † |
| Central venous infusion | 1.0 | (2467) | 4.5 | (1163) | <0.001 | |
| Temporary urinary catheterization | 1.0 | (2465) | 1.4 | (352) | <0.001 | |
aThe P values were obtained by the chi-square test for in-hospital death
bFor example, C-reactive protein, complement activity
cFor example, viral antibody tests, β-D-glucan assay
dFor example, blood type test, Coombs test
# Not significant
† Significantly associated with decreased risk of death
Result of logistic regression analysis in the derivation cohort and points assigned to each procedure
| Variable | β | exp(β) | 95 % CI |
| Points for procedure |
|---|---|---|---|---|---|
| Admission-precipitating diagnosis | |||||
| Acute myocardial infarction | Ref | ||||
| Congestive heart failure | −0.10 | 0.90 | 0.83 – 0.98 | 0.012 | |
| Acute cerebrovascular disease | −0.11 | 0.90 | 0.82 – 0.97 | 0.010 | |
| Gastrointestinal hemorrhage | −0.51 | 0.60 | 0.55 – 0.66 | <0.001 | |
| Pneumonia | 0.04 | 1.04 | 0.95 – 1.13 | 0.405 | |
| Septicemia | 0.73 | 2.07 | 1.87 – 2.28 | <0.001 | |
| Sex (female) | −0.12 | 0.89 | 0.86 – 0.91 | <0.001 | |
| Age | |||||
| <60 | Ref | ||||
| 60–69 | 0.35 | 1.43 | 1.33 – 1.53 | <0.001 | |
| 70–79 | 0.68 | 1.98 | 1.86 – 2.11 | <0.001 | |
| 80–89 | 1.14 | 3.12 | 2.94 – 3.31 | <0.001 | |
| ≥90 | 1.60 | 4.96 | 4.65 – 5.30 | <0.001 | |
| Charlson comorbidity index | |||||
| 0 | Ref | ||||
| 1 | 0.03 | 1.03 | 0.98 – 1.07 | 0.233 | |
| 2 | 0.18 | 1.20 | 1.16 – 1.24 | <0.001 | |
| ≥3 | 0.72 | 2.05 | 1.96 – 2.14 | <0.001 | |
| Procedure | |||||
| Invasive arterial pressure measurement | −0.30 | 0.74 | 0.68 – 0.81 | <0.001 | −3 |
| Blood tests (excluding coagulation) | −0.26 | 0.77 | 0.73 – 0.81 | <0.001 | −3 |
| Radiography | −0.20 | 0.82 | 0.79 – 0.86 | <0.001 | −2 |
| Urinalyses (excluding chemistry) | −0.18 | 0.84 | 0.81 – 0.87 | <0.001 | −2 |
| Temporary urinary catheterization | −0.18 | 0.84 | 0.74 – 0.94 | 0.004 | −1 |
| Endocrinology tests | −0.06 | 0.94 | 0.91 – 0.97 | <0.001 | −1 |
| Bacterial microscopy or culture | −0.05 | 0.95 | 0.91 – 0.99 | 0.019 | −1 |
| Acid-fast bacilli culture | −0.04 | 0.96 | 0.91 – 1.02 | 0.206 | # |
| Coagulation tests | −0.03 | 0.97 | 0.94 – 1.01 | 0.117 | # |
| Nucleic acid amplification tests | 0.01 | 1.01 | 0.93 – 1.09 | 0.842 | # |
| Bacterial drug susceptibility tests | 0.06 | 1.06 | 1.01 – 1.12 | 0.022 | 1 |
| Urine chemistry tests | 0.10 | 1.10 | 1.00 – 1.21 | 0.041 | 1 |
| Heart rate/respiration monitoring | 0.18 | 1.20 | 1.16 – 1.24 | <0.001 | 2 |
| Peripheral intravenous infusion | 0.18 | 1.20 | 1.16 – 1.24 | <0.001 | 2 |
| Computed tomography scan | 0.25 | 1.28 | 1.24 – 1.32 | <0.001 | 3 |
| Pulse oximetry | 0.29 | 1.33 | 1.29 – 1.37 | <0.001 | 3 |
| Gastric drainage tube insertion | 0.32 | 1.38 | 1.27 – 1.50 | <0.001 | 4 |
| Urinary catheter insertion | 0.47 | 1.60 | 1.55 – 1.66 | <0.001 | 5 |
| Central venous catheter insertion | 0.49 | 1.63 | 1.49 – 1.77 | <0.001 | 5 |
| Use of catecholamines or vasopressin | 0.70 | 2.02 | 1.92 – 2.13 | <0.001 | 8 |
| Sputum suction | 1.11 | 3.04 | 2.92 – 3.16 | <0.001 | 12 |
| Intratracheal intubation | 2.05 | 7.77 | 7.14 – 8.45 | <0.001 | 23 |
# No points assigned because of non-significance of the coefficient
CI – confidence interval
Fig. 1Distribution of the severity index and observed and expected death rates in the validation cohort. The box plots indicate the observed mortality rates and their 95 % confidence intervals
Fig. 2Calibration plot of the model predicting in-hospital death in the validation cohort
Results of subgroup analyses
| n | Mortality rate |
| 95 % CI | |
|---|---|---|---|---|
| Admission-precipitating diagnosis | ||||
| Acute myocardial infarction | 10 176 | 8.6 % | 0.821 | 0.806 – 0.836 |
| Congestive heart failure | 56 927 | 9.8 % | 0.709 | 0.702 – 0.716 |
| Acute cerebrovascular disease | 90 071 | 8.6 % | 0.801 | 0.796 – 0.807 |
| Gastrointestinal hemorrhage | 34 429 | 4.7 % | 0.791 | 0.780 – 0.801 |
| Pneumonia | 68 386 | 11.0 % | 0.733 | 0.727 – 0.739 |
| Septicemia | 9342 | 22.4 % | 0.699 | 0.686 – 0.711 |
| Admission by ambulance | ||||
| No | 166 979 | 6.5 % | 0.769 | 0.764 – 0.773 |
| Yes | 102 327 | 14.3 % | 0.744 | 0.740 – 0.748 |
| Referral from another institution | ||||
| No | 161 494 | 9.9 % | 0.769 | 0.766 – 0.773 |
| Yes | 107 808 | 8.8 % | 0.762 | 0.757 – 0.767 |
| Hospital type | ||||
| Non-academic | 225 479 | 9.6 % | 0.767 | 0.764 – 0.770 |
| Academic | 34 162 | 8.3 % | 0.759 | 0.749 – 0.769 |
CI – confidence interval
Fig. 3Calibration plots of models predicting in-hospital death in the validation cohort for six admissionprecipitating diagnoses (a, acute myocardial infarction; b, congestive heart failure; c, acute cerebrovascular disease; d, gastrointestinal hemorrhage; e, pneumonia; f, septicemia)